Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

被引:264
作者
Moody, SE
Sarkisian, CJ
Hahn, KT
Gunther, EJ
Pickup, S
Dugan, KD
Innocent, N
Cardiff, RD
Schnall, MD
Chodosh, LA [1 ]
机构
[1] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[6] Univ Calif Davis, UCD Ctr Comparat Med, Davis, CA 95616 USA
关键词
D O I
10.1016/S1535-6108(02)00212-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the impact of tumor progression on the reversibility of Neu-induced tumorigenesis, we have used the tetracycline regulatory system to conditionally express activated Neu in the mammary epithelium of transgenic mice. When induced with doxycycline, bitransgenic MMTV-rtTA/TetO-NeuNT mice develop multiple invasive mammary carcinomas, essentially all of which regress to a clinically undetectable state following transgene deinduction. This demonstrates that Neu-initiated tumorigenesis is reversible. Strikingly, extensive lung metastases arising from Neu-induced mammary tumors also rapidly and fully regress following the abrogation of Neu expression. However, despite the near universal dependence of both primary tumors and metastases on Neu transgene expression, most animals bearing fully regressed Neu-induced tumors ultimately develop recurrent tumors that have progressed to a Neu-independent state.
引用
收藏
页码:451 / 461
页数:11
相关论文
共 26 条
[1]   MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
CELL, 1986, 45 (05) :649-657
[2]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[3]  
BERGER MS, 1988, CANCER RES, V48, P1238
[4]   STOCHASTIC APPEARANCE OF MAMMARY-TUMORS IN TRANSGENIC MICE CARRYING THE MMTV/C-NEU ONCOGENE [J].
BOUCHARD, L ;
LAMARRE, L ;
TREMBLAY, PJ ;
JOLICOEUR, P .
CELL, 1989, 57 (06) :931-936
[5]   The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [J].
Cardiff, RD ;
Anver, MR ;
Gusterson, BA ;
Hennighausen, L ;
Jensen, RA ;
Merino, MJ ;
Rehm, S ;
Russo, J ;
Tavassoli, FA ;
Wakefield, LM ;
Ward, JM ;
Green, JE .
ONCOGENE, 2000, 19 (08) :968-988
[6]   The comparative pathology of human and mouse mammary glands [J].
Cardiff, RD ;
Wellings, SR .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1999, 4 (01) :105-122
[7]  
CARDIFF RD, 1993, CANCER SURV, V16, P97
[8]   Essential role for oncogenic Ras in tumour maintenance [J].
Chin, L ;
Tam, A ;
Pomerantz, J ;
Wong, M ;
Holash, J ;
Bardeesy, N ;
Shen, Q ;
O'Hagan, R ;
Pantginis, J ;
Zhou, H ;
Horner, JW ;
Cordon-Cardo, C ;
Yancopoulos, GD ;
DePinho, RA .
NATURE, 1999, 400 (6743) :468-472
[9]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[10]   c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations [J].
D'Cruz, CM ;
Gunther, EJ ;
Boxer, RB ;
Hartman, JL ;
Sintasath, L ;
Moody, SE ;
Cox, JD ;
Ha, SI ;
Belka, GK ;
Golant, A ;
Cardiff, RD ;
Chodosh, LA .
NATURE MEDICINE, 2001, 7 (02) :235-239